To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic diseases.

TAHITI couples CRISPR with transposable elements from plants to edit cash crops such as corn and soybean with reduced ...

CEO Serge Saxonov, PhD, acknowledged that its R&D operation “definitely ended up being impacted in a substantial way” while sales operations were less impacted since the company reorganized its sales ...

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows improvement from a rare metabolic disease.

Some of the most widely used methods include a tangential flow filter (TFF). Instead of flowing through a filter, a sample ...

Not designing with manufacturing in mind—even during early development—is a key reason fledgling biopharma companies fail.

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 ...

Montreal-based Nomic Bio broadens its proteomics technology to offer a 1,000-plex protein measurement service.

In this Revvity GENCast episode 2, experts will discuss applications of gene editing to improve scientists’ understanding of ...